Browse Health
License & Identifications

A medical license is required for a doctor to practice medicine in a particular state. Requirements vary by state but most require, at a minimum, post-graduate training in the doctor’s specific specialty. An NPI number is a national identifier unique to an individual health care provider and is managed by the Center for Medicare & Medicaid Services (CMS).

Patient Reviews

Patient comments (2)

The overall average patient rating of Dr. Mark Sanz is Excellent. Dr. Sanz has been reviewed by 4 patients who have provided 2 comments. The rating is 5 out of 5 stars.

Patient Ratings
Ease of Appointment 4.6
Promptness 5.0
Courteous Staff 5.0
Accurate Diagnosis 5.0
Bedside Manner 4.6
Spends Time with Me 4.1
Follows Up After Visit 4.6

Specialties & Research

Dr. Mark Sanz, MD is board certified in Cardiovascular Disease and Interventional Cardiology.

  • He has special expertise in 6 areas:
  • Acute Coronary Syndrome (ACS)
  • Heart Block
  • High Blood Pressure (Hypertension)
  • High Cholesterol (Hypercholesterolemia)
  • Stroke
  • Unstable Angina

Education & Awards

Dr. Sanz graduated from University of Chicago. He has 52 awards.

Principal Investigator, Symphony II trial of Sibrafiban (1st for patient enrollment in western U.S)
Principal Investigator, Gene Therapy in Chronic Stable Angina, 2003
ACC Quality Strategic Directions Committee 2005-7, oversee all Quality Initiatives/Documents at ACC
Co-Investigator, SPIRIT IV Trial of Drug-Eluting Stents, 2007-2008
Principal Investigator, CHOICE trial of high-risk carotid Stenting, 2008-2012
Principal Investigator, Reopro Trials including EPIC, Epilog, Epistent
National Quality Forum (NQF) CV Measures Project Steering Committee member 2010-2012
Steering Committee, National Board of Governors, Am College Cardiology 2004-6
Co-Investigator, CURRENT, Randomized trial with different doses Plavix post-stents, 2008-09
Director of Cardiology, International Heart Institute of MT, 2004-2005
Fellow, Society of Cardiac Angiography and Intervention (FSCAI)
Interventional Stroke Program, co-Director, MERCI program, 2009-10
Chair, Intl Heart Institute IT Committee, 2009-present
Academic affiliations/honors and committees
Principal Investigator, TIMI 38, Plavix vs. Prasugrel, Unstable Angina
Co-Chair, Rocky Mountain Heart Symposium, 2010
Principal Investigator, CREST Trial of Carotid Stents, 2004-2008
Medicine Committee, St. Patrick Hospital, 1990-1992
ACC Peripheral Artery Disease Committee member, 2006-2008
Institutional Review Board, St. Patrick Hospital, 1989-1994
Sub-Investigator EXCEL randomized trial of Left Main Stenting vs. CABG, 2012
Principal Investigator, Cogentus Trial comparing Plavix to Plavix/Prilosec for 1 year, 2008-9
Vice President, Western Montana Clinic 1996-97
Principal Investigator, RESCUE trial of Lovenox in Unst. Ang., 2003
Principal Investigator, CANOPY trial of Abbott Carotid stents in real world with 3 year f/u, 2012
Principal Investigator, Evalve registry, REALISM, 2008-present
Principal Investigator, PRESTO trial of tranilast in PTCA
Diplomate, National Board of Medical Examiners (7/81)
Diplomate, A.B.I.M., Interventional Cardiology (2001-2011)
Diplomate, American Board of Internal Medicine (9/84), 076702
Diplomate, A.B.I.M., Subspecialty in Cardiology (9/87)
NRC Certification in Nuclear Cardiology 2007
Patent Pending for Percutaneous Mitral Valve Repair, 2005
Recipient of $50,000 from Hearst Foundation for Telemedicine/EMR in December, 2006
Recipient of $700,000 Federal Appropriation for Telemedicine, OAT, FY 2005
Recipient of $300,000 Paul G. Allen Grant for Telemedicine in MT, 2004
Recipient of $60,000 grant for Telemedicine from Dennis and Phyllis Washington Foundation 2005
Recipient FY2009 Appropriation $300,000 for EHR/HIE development
Computer Committee Director, Western MT Clinic 1989-1997
Carotid Stent Investigational program, Director, 2002-present
Principal Investigator, TARGET trial of aggrastat vs. abciximab
Principal Investigator, Impact Trial (Integrilin)
Principal Investigator, CAPTURE Trial of High Risk Carotid Stents, 2004-2006
Principal Investigator, ABSORB trial of Dissolving Coronary Stents, 2012
ABIM Interventional Cardiology Board Reviewer 2004-2010
ACC Cardiovascular Recognition Program Committee 2007-2008
Fellow, American College of Cardiology (FACC)
Principal Investigator, ACT (Abrupt Closure Trial in PTCA) at St. Patrick Hospital
Co-Investigator, Xience V registry, 5-year F/U real world stenting with Xience DES, 2008
Principal Investigator, DELIVER trial of Taxol-coated stents
Principal Investigator, Evalve percutaneous mitral valve repair trial 2007-2008 (EVEREST II trial)
Co-recipient of $1.7 million Dept. of Defense grant for vascular graft research, FY 2005


Dr. Sanz has 1 hospital affiliations:

  • St Patrick Hospital and Health Sciences 

Similar doctors nearby

Dr. Joseph Knapp

Internal Medicine
37 years experience
Missoula, MT

Dr. Bradley Berry

Internal Medicine
16 years experience
Missoula, MT

Dr. Michael Reed

Internal Medicine
13 years experience
Missoula, MT

Dr. Alexander Jehle

Internal Medicine
12 years experience
Missoula, MT

Dr. James Maddux

Internal Medicine
17 years experience
Missoula, MT

Dr. Carolyn Goren

Internal Medicine
38 years experience
Missoula, MT
Search All Similar Doctors
Additional Information
Dr. Mark Louis Sanz MD is a male Internist, has 32 years of experience and practices in Cardiovascular Disease and Interventional Cardiology.
Where does Dr. Mark L. Sanz practice?
Dr. Mark Sanz has 1 office location.
Dr. Mark Sanz practices Cardiovascular Disease and Interventional Cardiology near Missoula, MT.
See Missoula Cardiologists.